outlook solid earn share
price hing core drug xtandi
action fine-tun estim still expect solid
perform overal maintain neutral rate lower target
price reflect chang valuat assumpt
invest overview think astella share price regain ground
amid increas investor confid earn underpin growth
core prostat cancer treatment xtandi though expect gener
version rival drug zytiga gain approv launch us
maintain neutral rate see risk xtandi prescript
number dwindl possibl xtandi supplant
zytiga gener even first-lin set well think
share price adequ reflect risk patent expir
vesicar tarceva
catalysts/risk addit circumst surround xtandi
focus also whether earn recoveri aid
approv file launch product identifi key post-poc
pipelin product may brief astella strateg
includ roxadustat anemia associ chronic kidney diseas
ckd dialysis/non-dialysi fezolinet menopause-rel vasomotor
symptom mr-vm gilteritinib recurr refractori acut
valuat updat valuat base year target
price base ep previous ep
forward price-to-earnings
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price upsid rate neutral target price analyst fumiyoshi sakai
profit tax
issuanc retir stock
net chang cash
number share mn
profit tax
cash equival
compani mention price
